Designs, develops, manufactures and markets the CoolGlide, Xeo and Solera product platforms for use by dermatologists, plastic surgeons, gynecologists and other qualified practitioners to offer safe, effective and non-invasive aesthetic treatments.
BATS data provided in real-time. NYSE, NASDAQ and AMEX data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates and Analyst Ratings provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
Cutera has been on my stock list for a long-time. I own the stock in my real port and I believe it will do very well despite it's recent 30%+ correction due to pre-announced earnings miss. Management is straight forward and is bottom line oriented.
The company will rectify the sales numbers in the subsequent quarters and will continue with its expansion. It's going to take a while before the stock is back to it's recent highs, but it'll happen in the next 12-18 months. In the next 5 years, the stock will outperform all the indexes.
In my opinion, the only major risk to the story is aggressive pricing from competitors and patent litigation results that are negative to CUTR (If Palomar loses the current litigation with Candela, Cutera is still obligated to pay royalties).
Management is straight forward? On January 31, 2007, CUTR issued guidance above analysts estimates. In late February CEO Kevin Connors led a stampede of insiders selling millions of dollars worth of stock in the company. On April 5, Cutera reversed itself, cutting earnings estimates for the first quarter nearly in half. The stock tanked 30% on the news. Think the insiders were just insanely lucky - nah, me either. Think they can they spell SOX? The SEC and securities litigation bar will have a field day with these guys.